Trial Profile
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Registrational; Therapeutic Use
- Acronyms POSEIDON
- Sponsors Aimmune Therapeutics; Stallergenes Greer plc
- 20 Nov 2023 Results published in the Stallergenes Greer media release.
- 20 Nov 2023 According to a Stallergenes Greer media release, full study data were published in the New England Journal of Medicine Evidence.
- 27 Feb 2023 Results reporting safety outcomes presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology